Stockscreener 앱 받기
11.07
0.63%
0.02
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Guggenheim Raises Price Target for Phathom Pharmaceuticals (PHAT) to $25 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Phathom Pharmaceuticals Hits Day High with 10.06% Surge in Stock Price - Markets Mojo
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-02-27 - Seeking Alpha
Phathom Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Decoding Phathom Pharmaceuticals Inc (PHAT): A Strategic SWOT In - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals (PHAT) Stock Analysis: A Look At Its 85.88% Potential Upside - DirectorsTalk Interviews
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 14.3% on Earnings Beat - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals Q4 2025 beats expectations, stock surges - Investing.com Nigeria
Phathom Pharmaceuticals Shares Rise After Q4 Loss Narrows, Revenue Rises - marketscreener.com
Phathom Q4 2025 slides: 217% revenue growth, profitability in sight By Investing.com - Investing.com UK
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.20 - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q4 Revenue $57.6M, vs. FactSet Est of $57.2M - marketscreener.com
PHATHOM PHARMA ($PHAT) Releases Q4 2025 Earnings - Quiver Quantitative
Phathom Pharma earnings beat by $0.34, revenue topped estimates - Investing.com UK
Phathom Pharmaceuticals : Fourth Quarter 2025 Earnings Call Presentation – February 2026 - marketscreener.com
Phathom Pharmaceuticals Q4 revenue slightly beats expectations - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals (PHAT) grows 2025 sales but remains deeply unprofitable - Stock Titan
Phathom Pharmaceuticals Earnings Review: Q4 Summary - Benzinga
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full - GlobeNewswire
Phathom Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance - Bitget
What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 E - GuruFocus
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6%Time to Sell? - MarketBeat
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 - The Manila Times
Drugmaker Phathom to break down 2025 results, update in Feb. 26 webcast - Stock Titan
Breakout Watch: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Volume Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit - MarketBeat
Phathom Pharmaceuticals (PHAT) CEO reports PSU vesting and tax share surrender - Stock Titan
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewswire
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment - Traders Union
(PHAT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stock Market Recap: What is Phathom Pharmaceuticals Incs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Intraday Trade Alerts - baoquankhu1.vn
Momentum Shift: Can NTST maintain its current growth ratePortfolio Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Aug Final Week: What is Phathom Pharmaceuticals Incs book value per share2025 Technical Overview & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Millennium Management LLC Reduces Stake in Phathom Pharmaceuticals Inc - GuruFocus
What are the risks of holding Phathom Pharmaceuticals Inc.2025 Dividend Review & Advanced Technical Analysis Signals - mfd.ru
Is Phathom Pharmaceuticals Inc. a cyclical or defensive stockPortfolio Performance Summary & Growth Focused Entry Reports - mfd.ru
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AIGH Capital Management LLC Acquires Shares of 429,000 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Aug Drivers: Is DENNs growth already priced inJuly 2025 Trade Ideas & Precise Buy Zone Tips - baoquankhu1.vn
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - 富途资讯
0.16%
자본화:
|
볼륨(24시간):